Ketamine Infusions for Bipolar Depression(KET-BD-Sustain Trial)

"This clinical research study is accepting applications from people between the ages of 21 to 65 suffering from bipolar disorder. Essential criteria for admission include: providing voluntary informed consent, meeting DSM-5 criteria and having an inadequate response to two or more first line treatment trials as per CANMAT guidelines, being in a current depressive episode with no psychotic features verified by a psychiatrist at the start of parent trial, receiving guideline concordant pharmacotherapy without recent changes and undergoing either antidepressant response (change in MADRS score ≥ 50% at day 14) or experiencing symptom remission (MADRS score < 12 on day 14)."

"Ketamine Hydrochloride scored a 2 on our scale given the limited data concerning its efficacy, but enough evidence of safety to place it in Phase 2."

"As listed on clinicaltrials.gov, this study is actively recruiting participants and has been since August 10th 2022. The listing was last updated on the preceding day (August 9th)."

"To participate in this research, the required age range is between 21 and 65 years old as set forth by the inclusion criteria."

"Affirmative. Per the information found on clinicaltrials.gov, this medical study has been open for recruitment since 8/10/2022 and was recently updated on 8/9/2022. The trial requires 60 participants to be recruited from 2 different sites."